Virus-like Particles for IVD and Pharmaceutical Development

Advancing diagnostic and vaccine development with virus-like particles

Supporting vaccine development and infectious disease research

Virus-like particles (VLPs) are non-infectious structures that mimic key structural characteristics of viruses while lacking the genetic material required for replication. Within diagnostic and pharmaceutical workflows, VLPs support assay development, vaccine research and reagent development. LGC's portfolio includes virus-like particles, antibodies, antigens and recombinant proteins that provide biologically relevant solutions for infectious disease research.

Learn more

Common challenges in infectious disease assay
and vaccine development

Supporting assay development with biologically relevant,
non-infectious materials can present a range of technical
and operational challenges.

Safe biological alternatives

Developing and validating assays often requires positive materials that can be handled safely without the risks associated with infectious viral samples. VLPs provide a non-infectious alternative while maintaining key structural characteristics of native viruses.

Biologically relevant reagents

Assay developers require reagents that accurately represent target pathogens and support robust assessment of assay performance during development and optimisation.

Native epitope presentation

VLPs that preserve native antigenic structure help support realistic assessment of antibody recognition and assay performance during development and verification activities.

Vaccine research support

Vaccine developers require biologically relevant reagents for investigating antigen presentation, immune responses and candidate vaccine performance across infectious disease programmes.

Emerging disease preparedness

New and evolving infectious disease targets can create demand for customised reagents, virus-like particles, antibodies and recombinant proteins aligned to specific research and development requirements.

Access to specialised reagents

Vaccine, diagnostic and therapeutic developers often require access to virus-like particles, antigens and antibodies to support research, product development and assay optimisation activities.

How LGC helps assay development and verification

Supporting assay development, verification and infectious disease research with
virus-like particles, recombinant proteins, antibodies and antigens.

Who we support

IVD assay developers, vaccine researchers and pharmaceutical developers seeking biologically relevant materials for assay development, validation and research applications.

What they need

Virus-like particles, recombinant proteins, antibodies, antigens and custom development support for infectious disease testing, vaccine research and biopharmaceutical development.

Explore related applications and technologies

Applications

Supporting diagnostic development, vaccine research and biopharmaceutical workflows.

IVD and Commercial Oligonucleotides

Technologies

Biologically relevant materials designed to support assay development, vaccine research and infectious disease studies.

Industries

Solutions supporting organisations across the clinical diagnostics, pharmaceutical and life sciences sectors.

Featured Resources

View all resources

Gloved laboratory hands holding a glass vial, representing virus-like particle development, vaccine research and diagnostic reagent production.

Featured Resources

View all resources

Virus-Like Particles in Research

Fact Sheet

Custom Services

Catalogue

Alphaviruses in Research and Diagnostics

Fact Sheet

Why choose LGC for virus-like particles

Supporting diagnostic and biopharmaceutical development with biologically relevant infectious disease reagents and recombinant proteins.

Comprehensive reagent portfolio

Access virus-like particles, recombinant proteins, antibodies and antigens to support assay development, vaccine research and therapeutic development workflows.

Infectious disease expertise

Leverage a broad infectious disease portfolio and scientific expertise spanning virus-like particles, recombinant proteins, antibodies and antigens for diagnostic, vaccine and therapeutic applications.

Custom development support

Custom recombinant proteins can be developed to support emerging infectious disease programmes, specialised assay requirements and unique research objectives.

Laboratory pipetting procedure involving a microcentrifuge tube, illustrating biological reagent development and virology research.

“VLPs were confirmed to be heterogeneous in size, morphology and maturation state. Yet, we show that many highly conformational and quaternary structure-dependent antibody epitopes found on virus particles are efficiently displayed on DENV1–4 VLP surfaces as well. Additionally, DENV VLPs can efficiently be used as antigens to deplete DENV patient sera from serotype-specific antibody populations.” (Metz et al., 2018).

Frequently asked questions

What are virus-like particles (VLPs)?

Virus-like particles are non-infectious structures that mimic the morphology and antigenic presentation of native viruses while lacking the genetic material required for replication. This makes them valuable tools for diagnostic assay development, vaccine research and infectious disease studies.

How are VLPs used in diagnostic assay development?

VLPs can support assay development, optimisation and verification by providing biologically relevant materials that closely resemble target viruses while remaining non-infectious.

Can VLPs support vaccine research?

Yes. VLPs are widely used in vaccine research because they present viral antigens in a structurally relevant format that can support investigation of immune responses and antigen presentation.

What infectious disease applications are supported by LGC's VLP portfolio?

LGC's portfolio supports a range of infectious disease applications, including diagnostic development, vaccine research, therapeutic development and basic research across multiple viral targets.

Can LGC support custom reagent development projects?

Yes. LGC offers custom development services for recombinant proteins and other specialised infectious disease reagents to support specific research and product development requirements.

Need support with virus-like particles?

Whether you are developing diagnostic assays, advancing vaccine research or investigating infectious disease targets, our specialists can help identify solutions that support your development and testing objectives.

Talk to our experts Read more

Virus-Like Particles and Recombinant Proteins for IVD and Pharma

Advancing diagnostic and vaccine development with virus-like particles